These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 26787567

  • 1. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M, Hillis A, Hammad A.
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [Abstract] [Full Text] [Related]

  • 2. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O.
    Int J Cardiol; 2012 Mar 22; 155(3):418-23. PubMed ID: 21106264
    [Abstract] [Full Text] [Related]

  • 3. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.
    Am Heart J; 2009 Mar 22; 157(3):576-83. PubMed ID: 19249432
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA, Almasood A, Alshurafah H, Alamri H, Tamim H.
    J Interv Cardiol; 2013 Feb 22; 26(1):90-6. PubMed ID: 22994682
    [Abstract] [Full Text] [Related]

  • 5. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E, Poh KK, Lu Q, Zhang JJ, Tan N, Hou XM, Ong HY, Azan A, Chen SL, Chen JY, Ali RM, Fang WY, Lau TW, Tan HC.
    Int J Cardiol; 2015 Dec 15; 201():237-42. PubMed ID: 26301645
    [Abstract] [Full Text] [Related]

  • 6. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE, Cellarier E, Aublet-Cuvelier B, Decalf V, Motreff P, Marcaggi X, Deteix P, Souweine B.
    Clin Nephrol; 2008 Dec 15; 70(6):475-84. PubMed ID: 19049703
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M, Cengiz H, Hoeltgen R, Wieczorek M, Boedeker RH, Scheibelhut C, Boening A.
    J Invasive Cardiol; 2013 Jun 15; 25(6):276-83. PubMed ID: 23735352
    [Abstract] [Full Text] [Related]

  • 8. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J, Rempinski D, O'Neill W, Kahn J.
    J Interv Cardiol; 2004 Jun 15; 17(3):159-65. PubMed ID: 15209578
    [Abstract] [Full Text] [Related]

  • 9. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
    Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F.
    Trials; 2009 Jun 29; 10():45. PubMed ID: 19563648
    [Abstract] [Full Text] [Related]

  • 10. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.
    Am Heart J; 2003 Dec 29; 146(6):E23. PubMed ID: 14661012
    [Abstract] [Full Text] [Related]

  • 11. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, Lee MH.
    Int J Cardiol; 2010 Feb 04; 138(3):239-45. PubMed ID: 18793808
    [Abstract] [Full Text] [Related]

  • 12. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P, Bianchi R, Caprile M, Sordelli C, Cappelli Bigazzi M, Palmieri R, Gigantino G, Limongelli G, Capozzi G, Cuomo S, Calabrò R.
    Minerva Cardioangiol; 2010 Feb 04; 58(1):35-40. PubMed ID: 20145594
    [Abstract] [Full Text] [Related]

  • 13. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
    Schmidt P, Pang D, Nykamp D, Knowlton G, Jia H.
    Ann Pharmacother; 2007 Jan 04; 41(1):46-50. PubMed ID: 17190844
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z, Verma A, White CJ, Grant AG, Collins TJ, Grise MA, Jenkins JS, McMullan PW, Patel RA, Reilly JP, Thornton SN, Ramee SR.
    Catheter Cardiovasc Interv; 2012 May 01; 79(6):921-6. PubMed ID: 21542122
    [Abstract] [Full Text] [Related]

  • 15. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F, Amhad M, Smalling RW, Sdringola S.
    Catheter Cardiovasc Interv; 2003 Mar 01; 58(3):336-41. PubMed ID: 12594698
    [Abstract] [Full Text] [Related]

  • 16. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial.
    Dvoršak B, Kanič V, Ekart R, Bevc S, Hojs R.
    Ther Apher Dial; 2013 Aug 01; 17(4):384-90. PubMed ID: 23931876
    [Abstract] [Full Text] [Related]

  • 17. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
    Baskurt M, Okcun B, Abaci O, Dogan GM, Kilickesmez K, Ozkan AA, Ersanli M, Gurmen T.
    Eur J Clin Invest; 2009 Sep 01; 39(9):793-9. PubMed ID: 19500141
    [Abstract] [Full Text] [Related]

  • 18. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O.
    Am Heart J; 2007 Sep 01; 154(3):539-44. PubMed ID: 17719303
    [Abstract] [Full Text] [Related]

  • 19. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ.
    Am Heart J; 2006 May 01; 151(5):1032.e9-12. PubMed ID: 16644332
    [Abstract] [Full Text] [Related]

  • 20. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G.
    J Am Coll Cardiol; 2010 May 18; 55(20):2201-9. PubMed ID: 20466200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.